Updated:
Pharco Pharmaceuticals
Pharco Pharmaceuticals is a member of Pharco Corporation, founded by Dr. Hassan Abbas Helmy in 1987. The company operates within a group of nine healthcare...
Pharco Pharmaceuticals
Pharco Pharmaceuticals is a member of Pharco Corporation, founded by Dr. Hassan Abbas Helmy in 1987. The company operates within a group of nine healthcare companies in the pharmaceutical field, developing, manufacturing, marketing, distributing, and exporting branded and generic drugs. Pharco Pharmaceuticals has invested in Naia as part of its Series A funding on October 19, 2015.
General information
Firm type
Company
Location
Region
Middle East
Country
Egypt
City
Alexandria
Corporate office
Alexandria, Egypt
Sector focus
Frequently asked questions
Who owns Pharco Pharmaceuticals?
Pharco Pharmaceuticals is a private Egyptian company. Its ultimate ownership structure is not publicly disclosed in the available sources.
What is Pharco's core business?
Pharco manufactures generic and branded generic pharmaceuticals, plus nutritional and vitamin products. It operates 11 companies across the pharmaceutical value chain (per the company's website).
How large is Pharco's production capacity?
The company reports producing 2.5 million packs daily, employing over 8,000 people, and exporting to more than 50 countries (per Pharco's website).
What role did Pharco play in Egypt's hepatitis C eradication?
Pharco was a major manufacturer of generic hepatitis C treatments, contributing to a national campaign that treated over 4 million patients (per company disclosures and WHO reports).
Does Pharco operate outside pharmaceuticals?
Public information focuses exclusively on pharmaceutical manufacturing and distribution. No evidence of real estate, venture capital, or other investment activities was found.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: